TRT + GLP-1 Together: Body-Recomp Interactions, Explained

The short version: the theory behind running testosterone replacement therapy (TRT) and a GLP-1 medication together is that the GLP-1 drives fat loss while testosterone supports muscle, so combined, the hope is better body recomposition with less muscle lost. That is a mechanistic rationale, not a proven protocol, and the direct trial evidence for the specific combination is limited. Both drugs are prescription-only and need coordinated clinical monitoring, so this is a conversation to have with your prescribers, not a stack to assemble on your own.

A quick note on what these drugs are before going further. TRT and GLP-1 medications are both prescription-only in the US, and TRT is a Schedule III controlled substance. This article explains how the two interact and what gets monitored; it does not recommend combining them and does not set or suggest any dose. Those decisions belong to licensed clinicians who know your full history.

What problem does each one solve?

GLP-1 medications are weight-loss and glucose-control drugs. The two most common are semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound). They reduce appetite and slow gastric emptying, and they can drive substantial weight loss over months.

TRT solves a different problem. TRT is exogenous testosterone given to raise serum testosterone back into the normal range in men with clinically diagnosed hypogonadism (low testosterone with symptoms). It is not a performance enhancer for men with normal levels, and a real diagnosis matters here.

Per the Endocrine Society, a hypogonadism diagnosis needs both symptoms and confirmed low testosterone. Specifically, it requires low total testosterone on at least two separate morning, fasting measurements, with the Endocrine Society defining low total T as below 264 ng/dL. The "two morning measurements plus symptoms" standard is the gate, and it is worth knowing whether you actually cleared it. Our TRT basics guide walks through how that diagnosis is made.

So the two drugs sit on opposite sides of body composition: one targets fat, the other supports muscle. That contrast is exactly why the combination gets discussed.

What is the muscle-loss problem on GLP-1s?

When you lose weight fast, not all of it is fat. Research suggests that roughly 25% to 40% of the weight lost on GLP-1 medications can come from lean mass rather than fat. Tirzepatide trials sit nearer the lower end (around 25% in the SURMOUNT-1 DXA substudy, reported in Diabetes Obesity and Metabolism in 2025), while some semaglutide analyses land nearer 40% (per a STEP 1 DXA analysis in the Journal of the Endocrine Society in 2021).

Those numbers sound alarming until you read the nuance, and the nuance matters a lot. "Lean mass" on a DXA scan is not pure skeletal muscle: it includes water, organs, and connective tissue, so a drop in lean mass is not the same as an equivalent drop in muscle. On top of that, in nearly all of these trials the lean-to-fat ratio actually improves, meaning the body becomes relatively leaner even as absolute lean mass falls. You are not necessarily ending up weaker; you are ending up smaller, with proportionally more fat gone.

It also helps to understand why lean mass drops, because the mechanism is mostly indirect. GLP-1 medications suppress appetite, which tends to cut protein intake, and rapid weight loss in a calorie deficit without enough protein and training is what catabolizes muscle. The medications are not "attacking" or directly wasting muscle. A direct catabolic effect of GLP-1s on human muscle is not established, and some preclinical data even hints that GLP-1 signaling could be muscle-protective. The advisory framing from the OMA/TOS/ACLM/ASN 2025 joint statement, echoed by groups like Mass General, points to behavior and deficit, not the drug directly stripping muscle.

If you want the full picture on this, the complete guide to GLP-1 muscle loss and our breakdown of fat loss versus muscle loss on GLP-1s go deeper than this section can.

Where does testosterone fit in?

Here is the theoretical hook. Testosterone supports muscle mass and strength, so if a GLP-1 is driving fat loss and pulling some lean mass along with it, the reasoning goes that adequate testosterone might help hold onto more of that muscle. Better fat loss, more muscle preserved, a cleaner recomposition: that is the pitch.

It is a plausible mechanistic rationale, and it is worth taking seriously as a hypothesis. But it needs heavy hedging. There is limited direct trial evidence for this specific combination, meaning we do not have a deep bench of studies that put people on both a GLP-1 and TRT and measured the recomposition benefit head-to-head against a GLP-1 alone.

This is an emerging area. Some clinicians and clinics do offer both therapies together, often for men who already have diagnosed low testosterone and separately want or need weight loss. That real-world use is not the same as proven efficacy for the combination. Treat the recomposition claim as a reasonable theory that providers are exploring, not as a settled protocol with a strong evidence base behind it.

How do TRT, GLP-1, and the combination compare?

The table below lays out the three scenarios side by side. Everything here is general and hedged; none of it is medical advice or a recommendation to combine.

Dimension	TRT alone	GLP-1 alone	Combined (theory)
Primary effect	Supports muscle mass and strength in diagnosed low T	Fat loss and appetite suppression	The hope: fat loss with more muscle support
Effect on fat mass	Modest changes possible; not a primary fat-loss drug	Substantial fat loss in many people	Fat loss driven mainly by the GLP-1
Effect on lean mass / muscle	Supports lean mass; not a guarantee of preservation	Some lean-mass loss common (research suggests ~25% to 40% of weight lost)	Theoretically more lean mass preserved; limited direct evidence
Key monitored risks	Rising hematocrit, estradiol shifts, PSA, lipids	GI side effects, lean-mass loss with rapid loss	Both sets of risks at once
Monitoring needs	Testosterone (total and free) plus hematocrit labs	Weight, body composition, tolerability	Coordinated monitoring of both, together
Prescription status	Prescription-only (Schedule III)	Prescription-only	Prescription-only, two prescriptions

The honest takeaway from the table: the combined column is the only one written in the conditional tense, because it is the only one without solid combination-trial backing.

What are the honest caveats?

The biggest one: testosterone is not a license to skip protein and resistance training. Those two levers are the proven ways to protect muscle during weight loss, and TRT does not replace them. The OMA/TOS/ACLM/ASN 2025 advisory is blunt that protein alone is likely inadequate without resistance training, which tells you how central training is to the whole equation.

For numbers, the same 2025 advisory points to a protein target in the range of 1.2 to 1.6 g/kg/day during active weight loss. On the training side, a meta-analysis found that resistance training preserved most of the lean mass that would otherwise be lost to caloric restriction compared with dieting alone. Protein and lifting do the heavy lifting here, both literally and figuratively.

So where does that leave TRT? As an adjunct at best, not a guarantee. TRT may support muscle, but it does not promise that muscle will be preserved during rapid GLP-1 weight loss, especially if protein and training are neglected. Anyone framing testosterone as a shortcut around the basics has the order of operations backward.

What needs monitoring when you run both?

This is a two-prescription situation, and that is the whole reason it demands more oversight than either drug alone. A provider running both should be watching several things in parallel rather than in isolation.

On the TRT side, the most-monitored lab is hematocrit, the percentage of your blood that is red blood cells. Testosterone stimulates red blood cell production, which thickens the blood, so a rising hematocrit is the classic TRT signal to watch. Alongside it, providers typically track total and free testosterone, estradiol, PSA, and lipids, per the Endocrine Society testosterone therapy guideline. If you are unclear on why both total and free testosterone get measured, our explainer on free versus total testosterone covers the distinction.

On the GLP-1 side, the relevant signals are the weight-loss rate and body composition, because losing weight too fast is one of the conditions that makes lean-mass loss more likely. Tracking fat versus lean over time, not just the scale, is how you would actually catch a muscle problem early.

There is one more wrinkle worth naming, and it cuts toward more monitoring, not less. Rapid fat loss can shift hormone labs on its own: values like SHBG and estradiol can change as fat mass drops, so the testosterone picture is not static while a GLP-1 is doing its work. Labs can shift, which is yet another argument for keeping eyes on the numbers throughout.

All of this is why coordination between prescribers matters so much. Ideally one provider manages both, or at minimum two providers who share your labs and know about each other's therapy. The interactions here are exactly the kind that get missed when two clinicians are each looking at half the picture.

Who is this conversation actually for?

If you are weighing this combination, the productive move is to bring specific questions to a provider rather than a request for a stack. A few worth asking:

• Is my low testosterone actually diagnosed by the standard (symptoms plus confirmed low morning total T on at least two measurements), or am I assuming it?
• How will you monitor my hematocrit and body composition while I am on both?
• How fast should I be losing weight to protect muscle, and what counts as too fast?
• Are my prescribers coordinated, and does each one know about the other therapy?
• What protein and resistance-training plan should support this, given that those are the proven muscle-preservation levers?

Those questions keep the focus where it belongs: on diagnosis, monitoring, and the basics that actually move body composition.

Where does Myo fit?

Running TRT and a GLP-1 at once is a two-injectable, fat-versus-muscle balancing act, and Myo is built to track exactly that combination, with dose logs, labs, and body-composition trends in one place. The point is to make the moving parts legible so you and your providers can see the whole picture, not half of it.

Concretely, Myo supports multi-medication tracking, a fat-versus-muscle split with a muscle-loss trend flag, and trending for labs like hematocrit and testosterone over time. It also includes protein coaching toward your target, resistance-training logging, and doctor-ready reports you can hand to coordinated providers. You can even view the medication-level pharmacokinetics across the week with the medication-level visualizer, so the timing of each injectable is visible at a glance.

To be clear about what Myo is not: it is a tracking and education tool only. It never prescribes and never sources medication, and it is not affiliated with the makers of any GLP-1 drug. If you want the recomposition framing applied to peptides specifically, our piece on body recomposition with peptides is a useful companion.

The bottom line

The theory is genuinely promising: a GLP-1 for fat loss, testosterone to support muscle, and the prospect of a cleaner recomposition than either alone. The honest counterweight is that direct evidence for this specific combination is limited, so it remains a mechanistic hope rather than a proven protocol. Protein and resistance training still do the heavy lifting, TRT is an adjunct at best, and the whole thing is a clinician-managed, two-prescription situation that needs coordinated monitoring of testosterone, hematocrit, estradiol, and body composition together.

References

• Endocrine Society, "Testosterone Therapy in Men With Hypogonadism" clinical practice guideline. https://www.endocrine.org/clinical-practice-guidelines/testosterone-therapy
• STEP 1 DXA analysis (semaglutide), Journal of the Endocrine Society, 2021.
• SURMOUNT-1 DXA substudy (tirzepatide), Diabetes Obesity and Metabolism, 2025, doi 10.1111/dom.16275.
• OMA/TOS/ACLM/ASN 2025 joint nutrition and protein advisory, PMC12264624.
• Resistance training preserves lean mass during caloric restriction (meta-analysis), PMC5946208.